Activities of Tobramycin and Polymyxin E against *Pseudomonas aeruginosa* Biofilm-Coated Medical Grade Endotracheal Tubes

Keiko Tarquinio, a,b,c,e Kelsey Confreda, a,b James Shurko, c Kerry LaPlante b,c,d

Pediatric Critical Care Medicine, Hasbro Children’s Hospital, Rhode Island Hospital, Providence, Rhode Island, USA; Rhode Island Infectious Diseases (RIDD) Research Program, Providence Veterans Affairs Medical Center, Providence, Rhode Island, USA; University of Rhode Island, Department of Pharmacy Practice, Kingston, Rhode Island, USA; Department of Medicine b and Department of Pediatrics, c,w Warren Alpert Medical School of Brown University, Providence, Rhode Island, USA

Indwelling medical devices have become a major source of nosocomial infections, especially *Pseudomonas aeruginosa* infections, which remain the most common cause of ventilator-associated pneumonia (VAP) in neonates and children. Using medical grade polyvinyl chloride endotracheal tubes (ETTs), the activity of tobramycin and polymyxin E was quantified in a simulated prevention and treatment static time-kill model using biofilm-forming *P. aeruginosa*. The model simulated three clinical conditions: (i) planktonic bacteria grown in the presence of antibiotics (tobramycin and polymyxin E) without ETTs, (ii) planktonic bacteria grown in the presence of *P. aeruginosa*, antibiotic, and ETTs (simulating prevention), and (iii) a 24-h-formed *P. aeruginosa* biofilm grown on ETTs prior to antibiotic exposure (simulating treatment). In the model simulating “prevention” (conditions 1 and 2 above), tobramycin alone or in combination with polymyxin E was more bactericidal than polymyxin E alone at 24 h using a concentration of greater than 2 times the MIC. However, after a 24-h-old biofilm was allowed to form on the ETTs, neither monotherapy nor combination therapy over 24 h exhibited bactericidal or bacteriostatic effects. Against the same pathogens, tobramycin and polymyxin E, alone or in combination, exhibited bactericidal activity prior to biofilm attachment to the ETTs; however, no activity was observed once biofilm formed on ETTs. These findings support surveillance culturing to identify pathogens for a rapid and targeted approach to therapy, especially when *P. aeruginosa* is a potential pathogen.

MATERIALS AND METHODS

**Bacterial isolates.** American Type Culture Collection (ATCC, Manassas, VA) strain 25668 was obtained. Reference strain PAO1 was obtained from Thomas Murray, Frank H. Netter MD School of Medicine, Quinnipiac University, North Haven, CT [20, 21]. Prior to use, all bacteria were stored in tryptic soy broth (TSB; Difco Laboratories, Sparks, MD) with 15% glycerol and frozen at −80°C. Both strains are prolific biofilm producers [22, 23].

**Antimicrobial agents.** Commercially available, chemical grade polymyxin E (lot 081M1525V) powder and chemical grade tobramycin (lot 090M1196V) powder were purchased from Sigma-Aldrich (St. Louis, MO). Tobramycin powder and polymyxin E powder were stored at 4°C. Both tobramycin and polymyxin E were diluted in sterile water, and a fresh stock was made each day and prior to every experiment. Tobramycin and polymyxin E were tested at one, two, four, and eight times their respective minimum inhibitory concentrations (MICs) in tryptic soy broth (TSB; Difco Laboratories, Sparks, MD) with 15% glycerol. Tobramycin and polymyxin E were tested against *P. aeruginosa* PAO1 and reference strain 25668.

**RESULTS**

**Static time-kill experiments.** Using clinically available ETTs, this study aimed both to assess the efficacy of antibiotics against planktonic versus biofilm-formed *P. aeruginosa* and to identify which antibiotic, alone or combination, demonstrates the best *in vitro* activity against *P. aeruginosa* in the context of VAP.

This study was presented as a poster at the 52nd Interscience Conference of Antimicrobial Agents and Chemotherapy, San Francisco, CA, 7 to 12 September 2012 [19].

Received 11 June 2013 Returned for modification 31 July 2013 Accepted 26 December 2013 Published ahead of print 30 December 2013

Address correspondence to Kerry LaPlante, KerryLaPlante@uri.edu.

Copyright © 2014, American Society for Microbiology. All Rights Reserved.

respective MICs at 0, 4, and 24 h after inoculation (24). Cation-adjusted Mueller-Hinton broth (CA-MHB; Difco Laboratories, Sparks, MD) supplemented with 25 mg/liter calcium, 12.5 mg/liter magnesium, and 0.25% dextrose (Fisher Scientific, Pittsburgh, PA) was used to obtain a suspension corresponding to a 0.7 to 0.8 McFarland standard to produce an initial inoculum of 5.5 to 6.0 × 10^6 CFU/ml. Colony counts were determined using tryptic soy agar (TSA; Difco, Becton, Dickinson Co., Sparks, MD) plates.

Susceptibility testing. MIC tests were performed in triplicate using broth microdilution in accordance with Clinical and Laboratory Standards Institute (CLSI) and National Committee for Clinical Laboratory Standards (NCCLS) guidelines (25, 26). The MIC was defined as the minimum concentration of antibiotic that would inhibit the visual growth of the isolated organism. Minimum bactericidal concentrations (MBC) were also determined in triplicate for each antimicrobial agent using NCCLS guidelines (26). Bacteria were quantified using CFU/ml, and 5-μl aliquots were used for determination of MBC after 24 h incubation at 37°C using TSA (27).

Endotracheal tubes (ETTs). Commercially available Sheridan uncuffed ETTs (Hudson RIC, Temecula, CA) (6.0-mm inner diameter [ID]) were obtained. Each ETT was cut into 0.6-cm-by-0.3-cm rectangular pieces (ETT chips) using a one-quarter-rectangle hand punch (Fiskars Corporation, Helsinki, Finland) and sterilized with ethylene oxide gas prior to use in preformed- and formed-biofilm time-kill experiments (23). For comparisons, we also tested commercially available PVC coupons (part number RD 128-PVC; Biosurface Technologies Corp., Bozeman, MT) for preformed-biofilm P. aeruginosa PAO1 (16-18).

Biofilm formation. Sterile ETT chips were placed in each well of a 24-well plate (BD Biosciences, San Jose, CA). The ETT chip was submerged with 2 ml of a final bacterial inoculum, either PAO1 or ATCC 25668, obtained as described above using TSB supplemented with 1% dextrose, 2% NaCl, and 25 mg/liter calcium (STSB) and a modified version of a previously described method (28). The well plate was incubated at 37°C under static conditions for 24 h to promote biofilm formation on ETT chips. After 24 h, each ETT chip was gently rinsed three times in sterile phosphate-buffered saline (PBS) (Fisher Scientific, Pittsburgh, PA).

Time-kill study. Using a 24-h time-kill study, three clinical conditions were modeled using P. aeruginosa strains PAO1 and 25668: (i) planktonic bacteria in the presence of the antibiotics tobramycin and polymyxin E, without ETTs, (ii) planktonic bacteria grown in the presence of P. aeruginosa, antibiotics, and ETTs (simulating prevention), and (iii) a 24-h-formed P. aeruginosa biofilm on ETTs prior to antibiotic exposure (simulating treatment). Each time-kill experiment was carried out in a minimum of triplicate iterations. All antimicrobial agents were tested at one, two, four, and eight times their respective MICs with starting inocula of 5.5 × 10^6 to 6.0 × 10^6 CFU/ml adjusted to McFarland standards using a Vitrek colorimeter (bioMérieux, Inc., Durham, NC) (18, 29).

Sample aliquots (0.1 ml) were removed from cultures at 0, 4, and 24 h after each tube was shaken using a vortexing device for 1 min to remove biofilm growth from the ETT chip (23). Antimicrobial carryover was accounted for by serial dilution (10- to 10,000-fold) of plated samples with normal saline or vacuum filtration. This methodology has a lower limit of detection of 2.0 log_10 CFU/ml (29). Control growth tubes for each organism were prepared without antibiotic and run in parallel to the antibiotic test tubes.

For single antimicrobial agents, bactericidal activity (99.9% kill) was defined as a ≥3 log_10 CFU/ml reduction at 24 h in colony count from the initial inoculum. Bacteriostatic activity was defined as a <3 log_10 CFU/ml reduction at 24 h in colony count from the initial inoculum, while inactivity was defined as no observed reduction from the initial inoculum (24). For antibiotics evaluated in combination, synergy was defined as a ≥2 log_10 CFU/ml decrease, indifference was defined as a 1 to 2 log_10 CFU/ml change (increase or decrease), and antagonism was defined as a >2 log_10 CFU/ml increase in growth compared to the most active single agent.

Data analysis. All statistical analyses were performed using SPSS statistical software (IBM SPSS statistics version 20, IBM Corporation, Armonk, NY). After 24 h of exposure to an antimicrobial agent(s), the biofilm formation was quantified and bacteria were counted at 4 h and 24 h (with a lower limit of detection 2.0 log_10 CFU/ml) to compare antimicrobial groups, concentrations, and strains using analysis of variance (ANOVA) followed by Tukey’s post hoc analysis. Multiple regressions for the association between substrates and CFU/ml were analyzed. A P value of ≤0.05 indicated statistical significance.

RESULTS

The MIC for tobramycin was 0.5 μg/ml and for polymyxin E was 2 μg/ml for both the PAO1 and 25668 strains. The MBCs for tobramycin were 4 and 32 μg/ml and for polymyxin E were 16 and 64 μg/ml, respectively, for the Pseudomonas PAO1 and ATCC 25668 strains.

In the planktonic time-kill study, tobramycin demonstrated bactericidal activity against both Pseudomonas isolates at 24 h, with average decrease of 3.81 ± 0.16 log_10 CFU/ml for all concentrations except 1 times the MIC for PAO1 (Fig. 1a and b). Polymyxin E demonstrated bacteriostatic activity at 2 times and 4 times the MIC (average decrease of 2.16 to 2.63 log_10 CFU/ml) and bactericidal activity at 8 times the MIC (average decrease of 3.07 to 3.56 log_10 CFU/ml) but inactivity at 1 times the MIC for both isolates at 24 h (Fig. 1c and d). The combination therapy at 2 times, 4 times, and 8 times the MIC demonstrated indifference, with >3.44 log_10 CFU/ml kill for PAO1 and >3.46 log_10 CFU/ml kill for 25668 at 24 h (Fig. 1e and f).

In the preformed-biofilm time-kill studies (simulating prevention) at 24 h, tobramycin demonstrated bactericidal activity against both Pseudomonas isolates (average decrease of >3.3 log_10 CFU/ml), except 1 times the MIC for 25668, which showed inactivity (1.02 ± 1.86 log_10 CFU/ml increase; Fig. 2a and b). Similarly, polymyxin E demonstrated bactericidal activity (average decrease of >3.08 log_10 CFU/ml) at greater than 2 times the MIC but bacteriostatic activity at 1 times the MIC for both isolates at 24 h (Fig. 2c and d). The combination of tobramycin and polymyxin E demonstrated indifferent activity at all concentrations for both isolates (Fig. 2e and f).

In formed-biofilm time-kill studies (simulating treatment) for PAO1, combination therapy at 4 times the MIC was significantly more active at 4 h than therapy with polymyxin E alone at 4 times the MIC (mean difference [MD] = 1.34; 95% confidence interval [CI], 2.4 to –0.3 log_10 CFU/ml; P = 0.004) and 8 times the MIC (MD = 1.45; 95% CI, 2.5 to –0.4 log_10 CFU/ml; P = 0.001). Similarly, combination therapy at 8 times the MIC was significantly more active at 4 h than therapy with polymyxin E alone at 8 times the MIC (MD = –1.23; 95% CI, –2.3 to –0.2 log_10 CFU/ml; P = 0.01). However, indifferent activity was observed at 24 h. Similarly, for 25668, combination therapy at 8 times the MIC was significantly more active than therapy with polymyxin E alone at 4 h (MD = –1.06; 95% CI, –1.7 to –0.4 log_10 CFU/ml; P < 0.001). However, indifferent activity was observed at 24 h. Once biofilm is formed, both single-agent and combination antibiotics resulted in inactivity or indifference (Fig. 3).

In addition to medical grade PVC ETTs, we assayed time kill using commercially available PVC coupons (16–18). A similar trend of bactericidal activity was demonstrated at 24 h with greater than 4 times the MIC of tobramycin (average decrease of >3.03
log_{10} CFU/ml) and with greater than 2 times the MIC of polymyxin E (average decrease of >3.1 log_{10} CFU/ml), but indifference was noted when the combination of tobramycin and polymyxin E was evaluated at 2, 4, and 8 times the MIC (average decrease of >3.2 log_{10} CFU/ml). ANOVA showed that there was a significant difference between substrates and CFU/ml at 4 h (MD = 0.08; 95% CI, 2.5 to 3.7 log_{10} CFU/ml; P = 0.041) (Table 1). Multiple-regression analysis demonstrated that there was a significant association between CFU/ml and the substrate at 4 h (partial eta squared [η] = 0.493; P < 0.001) and at 24 h (η = 0.208; P < 0.001). The overall model fit was R^2 = 0.954.

**DISCUSSION**

Ventilator-associated pneumonia, a common nosocomial infection often caused by bacteria that produce biofilm, results in increases in morbidity, medical costs, and multidrug-resistant organisms (2, 3, 30–33). In one study, adult patients with VAP were hospitalized longer (38 versus 13 days; P < 0.01), mortality rates were higher (50% versus 34%; P < 0.01), and hospital costs were greater ($70,568 versus $21,620; P < 0.01) than were seen with uninfected ventilated patients, with estimated VAP-attributable costs of $11,897 (33). However, limited diagnostic criteria and modification of ETTs make VAP prevention particularly challenging and difficult, especially for neonates and children (2).

In children, reintubation and tracheostomy insertion create the additional risk of damaging their small and fragile airway; therefore, reintubation or tracheostomy after a standard duration of intubation is not routinely practiced. Thus, the longer the ETTs remain in patients due to prolonged mechanical ventilation, the more likely biofilms are to develop and adhere (34–36). This bac-

**FIG 1** Time kill against planktonic *P. aeruginosa*. Data shown represent the results for tobramycin against planktonic *P. aeruginosa* PAO1 (a) and 25668 (b), polymyxin E against planktonic *P. aeruginosa* PAO1 (c) and 25668 (d), and the combination of tobramycin and polymyxin E against planktonic *P. aeruginosa* PAO1 (e) and 25668 (f). Results are presented as means ± standard deviations.
Material accumulation of biofilms on ETTs may become dislodged during simple routine care such as suctioning or due to ventilation airflow. Bacteria and biofilm that break off become planktonic and seed further in the airway, causing more-complicated pneumonia (8, 37).

One controversial approach to treatment of VAP is “selective decontamination of the digestive tract” with broad-spectrum intravenous (IV) antimicrobials (38, 39). However, IV prophylaxis is not widely accepted due to fear of creating antibiotic-resistant strains among VAP pathogens. In the pediatric population, one of the most common VAP pathogens is \textit{P. aeruginosa}, accounting for 17\% to 25\% of VAP cases (2, 4, 5). Our model is most consistent with the practice of direct instillation of liquid antimicrobial agents through the ETT as prophylaxis against or treatment of VAP caused by \textit{P. aeruginosa} compared to inhalation of nebulized antibiotics (40). Instillation treatments pose less risk of systemic toxicity than IV administration because antimicrobial agents can be delivered locally using ETTs or tracheostomy tubes in children and neonates. Moreover, instillation can deliver drug directly to the site of pneumonia whereas nebulized drug may adsorb on the ETT, permeate into the ETT wall, or remain in the proximal airway. Therefore, our study model using ETT chips is useful to help understand the effects of tobramycin and polymyxin E, alone or in combination, to treat VAP caused by \textit{P. aeruginosa}.

In our study, we examined \textit{P. aeruginosa} growth with or without the presence of medical grade polyvinyl chloride (PVC) ETT to evaluate the bactericidal effects of two antibiotics under the conditions of VAP. We found that under \textit{in vitro} conditions, the

\[ \text{FIG 2 Time kill against pre-biofilm-formed } \textit{P. aeruginosa}. \text{ Data shown represent the results for tobramycin against } \textit{P. aeruginosa} \text{ PAO1 (a) and 25668 (b), polymyxin E against planktonic } \textit{P. aeruginosa} \text{ PAO1 (c) and 25668 (d), and the combination of tobramycin and polymyxin E against } \textit{P. aeruginosa} \text{ PAO1 (e) and 25668 (f) in the presence of ETT chips. Results are presented as means } \pm \text{ standard deviations.} \]
bactericidal effect of tobramycin or polymyxin E monotherapy required greater than 2 times the MIC at 24 h for the prebiofilm condition (prevention). However, antibiotics demonstrated different levels of activity against the two different strains. For PAO1, tobramycin monotherapy and the combination approach were equally active for killing. For 25668, the combination therapy was more active than monotherapy for killing at 24 h (Fig. 2); this finding may be related to the biofilm-forming abilities of each bacterium.

Our study also demonstrated that two of the antibiotics tested either in monotherapy or in combination showed inactivity against or indifference to both Pseudomonas strains once biofilm was formed on ETTs (Fig. 3). This is in contrast to the conclusions drawn by Herrmann et al. using a 96-peg Calgary biofilm device in vitro showing that combination therapy with colistin-tobramycin was superior to monotherapy against Pseudomonas biofilm (41).

Many in vitro studies have used commercially available PVC coupons, which have different characteristics with respect to texture and flexibility (based on the plasticizer content compared to medical grade PVC ETTs). We hypothesized that bacterial colonies would form differently on commercially available PVC coupons compared to medical grade PVC ETTs. To capture Pseudomonas growth in relation to different material surfaces more accurately, we studied the same antibiotic therapy against Pseudomonas PAO1 using both PVC coupons and PVC ETTs. There was a significant association between CFU/ml and substrate at 4 and 24 h (Table 1); thus, the results showed the importance of

FIG 3 Time kill against biofilm-formed P. aeruginosa. Data shown represent the results for tobramycin against P. aeruginosa PAO1 (a) and 25668 (b), polymyxin E against planktonic P. aeruginosa PAO1 (c) and 25668 (d), and the combination of tobramycin and polymyxin E against P. aeruginosa PAO1 (e) and 25668 (f). Results are presented as means ± standard deviations.
utilizing the same device material to mimic VAP conditions to evaluate antibiotic activity on biofilm.

In conclusion, neither single nor combination therapy with tobramycin and/or polymyxin E demonstrated killing activity once *Pseudomonas* biofilm was already formed on ETTs; however, no antagonism was noted. Bactericidal effects against preformed biofilm (simulating prevention) in the presence of ETTs suggest that surveillance cultures could identify pathogens prior to biofilm formation and could allow prophylactic or targeted approaches to therapy, especially when *Pseudomonas* is a potential pathogen. In addition, this study demonstrated the importance of material choice in an *in vitro* time-kill study. Further investigation could incorporate wild-type strains as well as clinically feasible treatment options for VAP in children.

**ACKNOWLEDGMENTS**

This study was funded by PCCSDP (Pediatric Critical Care Scientist Development Program), through NIH 5K12HD047349-07, and supported by the Department of Pediatrics, Hasbro Children’s Hospital, Rhode Island Hospital.

**REFERENCES**

18. Clinical and Laboratory Standards Institute. 2013. Performance standards for antimicrobial susceptibility testing M100-S23, 23rd informa-

### Table 1: Comparison of changes at 4 h from 0 h growth control between endotracheal tube and polyvinyl chloride coupons

<table>
<thead>
<tr>
<th>Concn</th>
<th>Tobramycin</th>
<th>Polymyxin E</th>
<th>Tobramycin + polymyxin-E</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>ETT</td>
<td>PVC coupon</td>
<td>ETT</td>
</tr>
<tr>
<td>1× MIC</td>
<td>−2.81 ± 0.04</td>
<td>−2.82 ± 0.12</td>
<td>−3.44 ± 0.43</td>
</tr>
<tr>
<td>2× MIC</td>
<td>−3.97 ± 0.21</td>
<td>−0.71 ± 0.01</td>
<td>−3.92 ± 0.03</td>
</tr>
<tr>
<td>4× MIC</td>
<td>−3.97 ± 0.21</td>
<td>−1.23 ± 0.03</td>
<td>−3.92 ± 0.03</td>
</tr>
<tr>
<td>8× MIC</td>
<td>−3.97 ± 0.21</td>
<td>−1.06 ± 0.03</td>
<td>−3.92 ± 0.03</td>
</tr>
</tbody>
</table>

ETT, endotracheal tube; PVC, polyvinyl chloride.
26. NCCLS. 1999. Methods for determining bactericidal activity of antimi-
crobial agents; approval guideline M26-A, 1st ed. National Committee for 
Clinical Laboratory Standards, Wayne, PA.

27. LaPlante K, Rybak MJ. 2004. Impact of high-inoculum Staphylococcus 
aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, 
alone and in combination with gentamicin, in an in vitro pharmacody-

10.1002/9780471729259.mc01b01s00.

29. LaPlante K, Rybak MJ. 2004. Clinical glycopeptide-intermediate staph-
ylococci tested against arbekacin, daptomycin, and tigecycline. Diagn. Mi-
2004.06.014.

165.7.2105078.

due to ventilator-associated pneumonia or colonization with Pseudomo-
nas or Acinetobacter species: assessment by quantitative culture of sam-
http://dx.doi.org/10.1093/clinids/23.3.538.

nia in pediatric intensive care unit patients: risk factors and outcomes. 

33. Warren D, Shukla SJ, Olsen MA, Kollef MH, Hollenbeak CS, Cox MJ, 
Cohen MM, Fraser VJ. 2003. Outcome and attributable cost of ventila-
tor-associated pneumonia among intensive care unit patients in a subur-
.1097/01.CCM.0000063087.93157.06.

34. Levine SA, Niederman MS. 1991. The impact of tracheal intubation on 
523–543.

A, Philips JI. 1999. The presence and sequence of endotracheal tube 

36. Gibbs K, Holzman IR. 2012. Endotracheal tube: friend or foe? Bacteria, 
the endotracheal tube, and the impact of colonization and infection. Se-
.008.

37. Bauer TT, Torres A, Ferrer R, Heyer CM, Schultzze-Werninghaus G, 
between pneumonia and the persistence of pathogens. Monaldi Arch. 

38. Bonten MJ. 2002. Strategies for prevention of hospital-acquired pneumo-
nia: oral and selective decontamination of the gastrointestinal tract. Se-
2002-35719.

39. van Essen E, de Jonge E. 2011. Selective decontamination of the digestive 

40. Brown RB, Kruse JA, Counts GW, Russell JA, Christou NV, Sands ML. 
1990. Double-blind study of endotracheal tobramycin in the treatment of 
gram-negative bacterial pneumonia. The Endotracheal Tobramycin 
.org/10.1128/AAC.34.2.269.

Molin S, Riethmuller J, Doring G. 2010. Colistin-tobramycin combina-
tions are superior to monotherapy concerning the killing of biofilm Pseu-
.1086/656788.

Tobramycin and Polymyxin E against P. aeruginosa

March 2014 Volume 58 Number 3 aac.asm.org 1729